Key Highlights

  • CLRO shares trading down 15.65% to $4.22 today.
  • The Merger agreement with Cortigent, a Subsidiary of Vivani Medical, is dated July 1, 2026.
  • ClearOne plans to issue 12,500,000 shares to Vivani as merger consideration.
  • A planned unit offering of $10.0 million to $15.0 million is priced at $3.50 per unit.
  • The company reported about $0.7 million in cash at the end of 2025.

No Announcement Identified for the 15.65% Slide in ClearOne Shares

ClearOne (NASDAQ:CLRO) shares are trading down 15.65% today at $4.22, and no company-specific announcement explaining the move was identified. The stock is a Penny Stock with a market Capitalization that was listed near $14.7 million earlier this week, when it was changing hands near $5.49.

The 52-week range runs from $1.62 to $16.50, reflecting the Volatility that has followed a 1-for-15 reverse split in June 2025 and a major restructuring of the business.

Cash, cash equivalents and restricted cash totaled about $0.7 million as of December 31, 2025, and remaining activities include legacy product support, public-company compliance and collecting receivables.

From Conferencing Products to a Pending Merger With Cortigent

ClearOne once designed and marketed professional audio conferencing, microphone and video collaboration products from Salt Lake City, Utah. It sold substantially all operating Assets and intellectual property to Biamp Systems in October 2025 and no longer manufactures or sells products.

Under a July 1, 2026 agreement, a merger subsidiary will combine with Cortigent, which will become a wholly owned ClearOne subsidiary. Cortigent is a subsidiary of Vivani Medical (NASDAQ:VANI), which will receive 12,500,000 ClearOne shares, while advisors are set to receive 855,000 shares.

Stockholders approved the share issuance on August 25, 2026, ahead of closing. Completion still depends on the financing, Nasdaq listing approval and reconstituting the board and management, and ClearOne may owe a $250,000 termination fee in certain circumstances.

A new chief financial officer was hired on July 31, 2026, with the appointment effective upon completion of the Cortigent acquisition.

Unit Offering at $3.50, Dilution and Going Concern Doubt

The company filed to sell between 2,857,143 and 4,285,714 units at $3.50 each, with every unit holding one share and one Warrant exercisable at $10.00 for six months. Gross proceeds would range from $10.0 million to $15.0 million, and the $10.0 million minimum is required to close.

Shares outstanding of 2,675,412 would rise to between 5,532,554 and 6,961,126 after the offering, before any warrant exercises or merger shares. Proceeds are earmarked for repaying a loan, developing the Orion and Stroke Recovery systems, manufacturing, and working capital.

The company's auditor has expressed substantial doubt about its ability to continue as a going concern, and the company received a Nasdaq continued-listing deficiency notice in April 2026. The stock now trades above the offering price.

Financing, Listing Approval and November 13 Earnings Frame the Next Steps for ClearOne

With no identified trigger for today's drop, investors are left to weigh the pending financing, dilution and listing conditions that stand between ClearOne and a completed merger. The agreement allows termination if it is not completed within 180 days of July 1, 2026.

The next scheduled datapoint is the earnings report, estimated for November 13, 2026. Any pricing or closing of the offering would also be closely watched. Updates on the Nasdaq listing review would matter as well.